Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week extension trial of NN5401 versus insulin glargine in adults with type 2 diabetes mellitus
2009-015839-33Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of insulin degludec, insulin aspart and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Long-term safety and tolerability of NN5401 versus insulin glargine. Started Mar 2010; status: completed.
02
Drugs
insulin degludecinsulin aspartinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-015839-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015839-33.